Octagam (intravenous normal human immunoglobulin) / Octapharma  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Octagam (intravenous normal human immunoglobulin) / Octapharma
NCT03339778: The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Completed
N/A
15
NA
IMMUNOe Research Centers
Primary Immunodeficiency
11/16
09/17
NCT01859754: Octagam 5% Versus Comparator Post Marketing Trial

Completed
N/A
623
US
Octagam 5%, Other marketed IVIG product
Octapharma
Primary Immune Deficiency Disorder
05/19
05/19
GAM 10-06, NCT02303093: Non-Interventional Study on the Tolerability and Efficacy of IVIG

Completed
N/A
344
Europe, Canada
Octagam IVIG 5% or 10%, Panzyga
Octapharma
Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG
06/20
06/20

Download Options